Biology is programmable.
Precision is achievable.
Speed is possible.
The next generation of cancer therapies will come from reimagining what a therapeutic can be.
We operate at the frontier of artificial intelligence, bioengineering, and translational medicine, decoding cancer persistence and engineering precision immunotherapies that conventional drug discovery cannot produce.
"We are fighting to be the reason a patient comes home and makes their loved ones smile again."
A closed-loop AI drug discovery platform.
We design, screen, and generate physical candidate libraries, validating them directly in our wet labs. We continuously re-train our models into verified, real-world efficacy.
Our platform learns from every experiment, sharpening with every cycle to produce candidates optimised for efficacy and selectivity. Our initial therapeutic focus targets complex disease microenvironments where existing immunotherapy approaches face persistent resistance mechanisms, challenges that our closed-loop platform is specifically architected to bypass and overcome.
ARIA's closed-loop platform compresses AI drug discovery from a multi-year process into an iterative, months-long engineering cycle.
Programmable by design.
Every candidate is specified. The system engineers around what the biology reveals.
Precise by construction.
Efficacy and selectivity are first-order constraints built into the design process.
Scalable by automation.
Each cycle expands the architecture. The system compounds rather than resets with every new input.
ARIA Therapeutics exists to build a fully programmable therapeutic engine.
Our goal is to compress AI drug discovery and development timelines from years to months and deliver precision immunotherapy treatments to patients who cannot afford to wait.
Enquiries are welcome.
Scientific collaboration, partnership, capital allocation, and operating roles, please write directly.